Compounds > 3,4-dihydroxyphenylacetic acid

3,4-dihydroxyphenylacetic acid and ecopipam

3,4-dihydroxyphenylacetic acid has been researched along with ecopipam in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnett, A; Berger, JG; Chipkin, RE; Coffin, VL; Iorio, LC; McQuade, RD1
Emmi, A; Rajabi, H; Stewart, J1

Other Studies

2 other study(ies) available for 3,4-dihydroxyphenylacetic acid and ecopipam

ArticleYear
Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
    The Journal of pharmacology and experimental therapeutics, 1988, Volume: 247, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Benzazepines; Catalepsy; Dogs; Dopamine; Dopamine Antagonists; Homovanillic Acid; Male; Mice; Prolactin; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1; Stereotyped Behavior; Vomiting

1988
Behavioral and neurochemical recovery from partial 6-hydroxydopamine lesions of the substantia nigra is blocked by daily treatment with D1/D5, but not D2, dopamine receptor antagonists.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 1997, May-15, Volume: 17, Issue:10

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Benzazepines; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Homovanillic Acid; Male; Microdialysis; Oxidopamine; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D5; Substantia Nigra; Sympatholytics

1997